Global Director, Advocacy & Market Development

The Global Director, Advocacy & Market Development (Biologics) leads the global advocacy for severe asthma and non‑branded market development agenda. 

 

The role is responsible for: 

• Building credible, science‑led advocacy across pulmonology and immunology communities with a strong focus on Eosinophilic Inflammation 

• Leading global non-branded market development initiatives to improve diagnosis, optimize care pathways, and enable sustained biologic adoption, focused on International markets and China. 

• Partnering closely with Medical, Commercial and priority markets to translate strategy into measurable impact and scalable execution. 

• This position reports into Global Commercial Head Fasenra and operates in close alignment with Medical Affairs and Key Market Teams. 

Global Advocacy Program (Eosinophilic Inflammation ): Lead a global, science-driven advocacy program that mobilizes the respiratory and immunology communities around improved patient outcomes in eosinophilic diseases (Severe Asthma, EGPA and HES) 

• Develop and execute the global Fasenra advocacy strategy  aligned with brand strategy and lifecycle priorities 

• Build and evolve trusted relationships with Key External Experts (KEEs) through the Global EOS Science Group and respiratory disease forums 

• Shape and amplify the eosinophilic inflammation narrative in close collaboration with Global Medical and Brand teams, ensuring it’s credible, consistent, and locally actionable  

• Co-create scientific advocacy content and external education initiatives, in partnership with Medical Affairs 
   

Market Development Program (Unbranded): Lead the non-branded market development agenda to help redefine severe asthma care and accelerate adoption of biologic-ready patient pathways.  

• Lead the global non-branded market development strategy to ensure bio-eligible patients will have access to biological treatment options 

• Identify and address key barriers across the patient journey optimizing diagnosis, referral and Guideline Directed Medical Therapy 

• Partner with Medical, Access and Health Economics teams to co-create priority system change initiatives 

• Collaborate with respiratory authorities, KEEs, and relevant policymakers